Advertisement
Advertisement
MREO
Mereo BioPharma Group plc - ADR
0.28
USDSponsored
0.00
+0.93%
Nov 06, 15:59 UTC -5
Closed
After-Market
0.28
0.00
0.00%
Mereo BioPharma Group plc - ADR (MREO) Earnings
MREO Earnings Reports
Positive Surprise Ratio
MREO beat 3 of 9 last estimates.
33%
Next Report
Next Week
Date of Next Report
Nov 09, 2026
Estimate for Q3 26 (Revenue/ EPS)
--
/-$0.01
Implied change from Q2 26 (Revenue/ EPS)
--
/--
Implied change from Q3 25 (Revenue/ EPS)
--
/--
Mereo BioPharma Group plc - ADR earnings per share and revenue
On Aug 11, 2026, MREO reported earnings of -0.01 USD per share (EPS) for Q2 26, missing the estimate of 0.00 USD, resulting in a -21.95% surprise. Revenue reached --, compared to an expected 2.38 million, with a -100.00% difference. The market reacted with a +12.15% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 8 analysts forecast an EPS of -0.01 USD, with revenue projected to reach -- USD, implying an increase of 0.00% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
INmune Bio Inc. Common stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.14
Actual
-$0.17
Surprise
-13.64%
Moderna, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$1.27
Actual
$0.38
Surprise
+129.79%
Vera Therapeutics, Inc. Class A Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$1.65
Actual
-$1.30
Surprise
+21.33%
Novavax Inc
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.34
Actual
-$0.19
Surprise
+44.56%
Eton Pharmaceutcials, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.31
Actual
$1.06
Surprise
+232.50%
Castle Biosciences, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.37
Actual
-$0.13
Surprise
+65.32%
Monte Rosa Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.29
Actual
$0.03
Surprise
+110.09%
PUMA BIOTECHNOLOGY INC
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.09
Actual
$0.15
Surprise
+63.40%
Allogene Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.15
Actual
-$0.15
Surprise
+0.33%
Arcturus Therapeutics Holdings Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.69
Actual
-$0.26
Surprise
+62.44%
FAQ
What were Mereo BioPharma Group plc - ADR's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Mereo BioPharma Group plc - ADR reported EPS of -$0.01, missing estimates by -21.95%, and revenue of $0.00, -100% below expectations.
How did the market react to Mereo BioPharma Group plc - ADR's Q2 2026 earnings?
The stock price moved up 12.15%, changed from $0.27 before the earnings release to $0.31 the day after.
When is Mereo BioPharma Group plc - ADR expected to report next?
The next earning report is scheduled for Nov 09, 2026.
What are the forecasts for Mereo BioPharma Group plc - ADR's next earnings report?
Based on 8
analysts, Mereo BioPharma Group plc - ADR is expected to report EPS of -$0.01 and revenue of -- for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.